Raymond James Financial
LSTA icon

Raymond James Financial’s Lisata Therapeutics LSTA Stock Holding History

Raymond James Financial’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6
Closed -$17 – 5964
2025
Q2 		$17 Buy
+6
New +$14 ﹤0.01% 6929

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Raymond James Financial's LSTA Position: Q3 2025 in Review

Raymond James Financial sold out of Lisata Therapeutics (LSTA) in Q3 2025, closing a stake of 6 shares — an estimated $17 sold.

Raymond James Financial first reported a position in LSTA in Q2 2025 and held it in 1 quarter. The position peaked at $17 in Q2 2025. 21 funds tracked by Wall St. Rank hold LSTA as of Q3 2025.

  • Raymond James Financial reported no remaining Lisata Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 6 Lisata Therapeutics shares in Q3 2025, an estimated $17.
  • Raymond James Financial first reported a position in Lisata Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Lisata Therapeutics position peaked at $17 in Q2 2025.
  • 21 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.